title: [Adjuvant chemotherapy].
abstract: The authors treated 10 advanced renal cell carcinoma with circadian venous continuous infusion of 5-Fluoro 2-Deoxyuridine (FUDR). The drug was delivered by Medtronic Synchromed implantable pump in 14-day cycles alternating with 14-day intervals of physiologic saline infusion. Of the patient observed for at least 8 months (range: 8-32, median: 22.1) 1 showed progression. Circadian continuous central venous infusion of FUDR is minimally toxic. The FUDR can be delivered safely and conveniently in this way for long spans. This therapy is administrated in on entirely out patient setting, and associated with a normal quality of life.
authors.affiliation: Istituto di Urologia, Università di Milano.
authors.forename: A
authors.initials: A
authors.lastname: Del Nero
authors.forename: A
authors.initials: A
authors.lastname: Mandressi
authors.forename: G
authors.initials: G
authors.lastname: Longo
authors.forename: M
authors.initials: M
authors.lastname: Cogni
authors.forename: B
authors.initials: B
authors.lastname: Mangiarotti
authors.forename: V
authors.initials: V
authors.lastname: Buzzetti
authors.forename: R
authors.initials: R
authors.lastname: Russo
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005467:Floxuridine / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D015918:Infusion Pumps, Implantable; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D013997:Time Factors
chemical_list: D005467:Floxuridine
vernacular_title: Chemioterapia adiuvante.